Literature DB >> 10521836

Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality).

C Mansfield1, S Hopfer, T M Marteau.   

Abstract

The aims of this systematic literature review are to estimate termination rates after prenatal diagnosis of one of five conditions: Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes, and to determine the extent to which rates vary across conditions and with year of publication. Papers were included if they reported (i) numbers of prenatally diagnosed conditions that were terminated, (ii) at least five cases diagnosed with one of the five specified conditions, and (iii) were published between 1980 and 1998. 20 papers were found which met the inclusion criteria. Termination rates varied across conditions. They were highest following a prenatal diagnosis of Down syndrome (92 per cent; CI: 91 per cent to 93 per cent) and lowest following diagnosis of Klinefelter syndrome (58 per cent; CI: 50 per cent to 66 per cent). Where comparisons could be made, termination rates were similar in the 1990s to those reported in the 1980s.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  1999        PMID: 10521836

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  32 in total

1.  Exploring adoption with clients: the need for adoption education within the genetic counseling profession.

Authors:  Cassandra L Perry; Martha J Henry
Journal:  J Genet Couns       Date:  2010-03-16       Impact factor: 2.537

2.  Current estimate of Down Syndrome population prevalence in the United States.

Authors:  Angela P Presson; Ginger Partyka; Kristin M Jensen; Owen J Devine; Sonja A Rasmussen; Linda L McCabe; Edward R B McCabe
Journal:  J Pediatr       Date:  2013-07-23       Impact factor: 4.406

3.  A qualitative exploration of mothers' and fathers' experiences of having a child with Klinefelter syndrome and the process of reaching this diagnosis.

Authors:  Elyssia Bourke; Pamela Snow; Amy Herlihy; David Amor; Sylvia Metcalfe
Journal:  Eur J Hum Genet       Date:  2013-05-22       Impact factor: 4.246

4.  Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA.

Authors:  Dagmar Tapon
Journal:  J Genet Couns       Date:  2009-11-03       Impact factor: 2.537

5.  The Evolution of Spina Bifida Treatment Through a Biomedical Ethics Lens.

Authors:  Tal Levin-Decanini; Amy Houtrow; Aviva Katz
Journal:  HEC Forum       Date:  2017-09

6.  Variables influencing pregnancy termination following prenatal diagnosis of fetal chromosome abnormalities.

Authors:  Anne Hawkins; Ana Stenzel; Joanne Taylor; Valerie Y Chock; Louanne Hudgins
Journal:  J Genet Couns       Date:  2012-09-23       Impact factor: 2.537

Review 7.  Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature.

Authors:  Candice Y Johnson; Margaret A Honein; W Dana Flanders; Penelope P Howards; Godfrey P Oakley; Sonja A Rasmussen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-10-25

8.  Support Desired by Women Following Termination of Pregnancy for a Fetal Anomaly.

Authors:  Aarti Ramdaney; Syed S Hashmi; Manju Monga; Rebecca Carter; Jennifer Czerwinski
Journal:  J Genet Couns       Date:  2015-04-02       Impact factor: 2.537

Review 9.  Measuring paternal discrepancy and its public health consequences.

Authors:  Mark A Bellis; Karen Hughes; Sara Hughes; John R Ashton
Journal:  J Epidemiol Community Health       Date:  2005-09       Impact factor: 3.710

10.  Advances in medical technology and creation of disparities: the case of Down syndrome.

Authors:  Babak Khoshnood; Catherine De Vigan; Véronique Vodovar; Gérard Bréart; François Goffinet; Béatrice Blondel
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.